A retrospective study of Food and Drug Administration's (FDA) Adverse Events Reporting System (FAERS) to assess hepatitis B reactivation occurring with PD-1/PD-L1 inhibitors
Latest Information Update: 08 Feb 2022
At a glance
- Drugs Atezolizumab (Primary) ; Avelumab (Primary) ; Durvalumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Cancer
- Focus Adverse reactions
- 08 Feb 2022 New trial record